直肠癌对PSMA放射性配体呈强摄取:是谁给了PSMA一个「S」
本文报告一例71岁新诊断直肠腺癌伴肝转移患者,化疗后再分期显示直肠原发灶反应良好而肝转移进展。因患者有前列腺癌病史,行Ga-PSMA-HBED-CC PET/CT无创评估肝转移,但肝转移与直肠原发灶均见放射性配体摄取(分别为中度与强),无法明确区分肿瘤来源;随后肝活检示肠道来源低分化腺癌。
要点
- 直肠腺癌原发灶对PSMA放射性配体呈强摄取。
- 肝转移灶亦见中度PSMA放射性配体摄取。
- PSMA PET/CT无法明确区分肝转移与直肠原发灶的肿瘤来源。
核心结论
- 直肠腺癌原发灶可对PSMA放射性配体呈强摄取,肝转移灶呈中度摄取,导致PSMA PET/CT无法明确区分肿瘤来源。
研究设计与样本
- 本文为病例报告,报告一例71岁新诊断直肠腺癌伴肝转移、并有前列腺癌病史的患者。
主要发现
- 化疗后再分期显示直肠原发灶反应良好,而肝转移进展。
- Ga-PSMA-HBED-CC PET/CT显示肝转移灶呈中度放射性配体摄取,直肠原发灶呈强摄取。
- 随后肝活检示肠道来源低分化腺癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present a case of a 71-year-old patient with newly diagnosed rectal adenocarcinoma and hepatic metastases. Restaging after chemotherapy revealed a good response of the rectal primary while liver metastases were progressive. As the patient also had a history of prostate cancer, a Ga-PSMA-HBED-CC PET/CT scan was performed to noninvasively further assess hepatic metastases. However, a definite differentiation between tumor entities was not possible because not only the liver metastases but also the rectal primary showed radioligand uptake (moderate and strong, respectively). Consecutive liver biopsy revealed a poorly differentiated adenocarcinoma of intestinal origin.
引用
- Stoykow C, Huber-Schumacher S, Almanasreh N, et al. Strong PSMA Radioligand Uptake by Rectal Carcinoma: Who Put the "S" in PSMA? Clin Nucl Med. 2017. PMID: 27997423. doi:10.1097/RLU.0000000000001484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。